EFFICACY AND SAFETY OF PONATINIB USED IN FRAIL CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS OUTSIDE OF CLINICAL TRIALS

被引：0
|
作者：
Breccia, M. [1 ]
Abruzzese, E. [2 ]
Accurso, V. [3 ]
Castagnetti, F. [4 ]
Galimberti, S. [5 ]
Bonifacio, M. [6 ]
Gangemi, D. [7 ]
La Barba, G.
Sora, F. [8 ]
Tiribelli, M. [9 ]
Iurlo, A. [10 ]
Luciano, L. [11 ]
Gozzini, A. [12 ]
Pezzullo, L.
Rossi, A. Russo [13 ]
Sgherza, N. [14 ]
Foa, R. [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Policlin Umberto I, Hematol, Rome, Italy
[2] S Eugenio Hosp, Rome, Italy
[3] Policlin Giaccone, Hematol, Palermo, Italy
[4] Univ Bologna, Inst Hematol L&A Seragnoli, Univ Hosp, Bologna, Italy
[5] Pisa Univ, Hematol, Pisa, Italy
[6] Univ Verona, Sect Hematol, Dept Med, Verona, Italy
[7] Fabrizio Spaziano Hosp, Frosinone, Italy
[8] Cattolica Sacro Cuore Univ, Rome, Italy
[9] Udine Univ, Hematol, Udine, Italy
[10] Univ Milan, IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Milan, Italy
[11] Federico II Univ Naples, Naples, Italy
[12] Univ Firenze, AOU Careggi, Florence, Italy
[13] Univ Bari, Hematol & Transplants Unit, Bari, Italy
[14] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P096
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [41] Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd
    Larson, Richard A.
    Bunworasate, Udomsak
    Turkina, Anna G.
    Goldberg, Stuart L.
    Dorlhiac-Llacer, Pedro
    Lopez, Jose L.
    Kantarjian, Hagop M.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Hoenekopp, Albert
    Blakesley, Rick E.
    Yu, Richard
    Gallagher, Neil J.
    Clark, Richard E.
    Hughes, Timothy P.
    BLOOD, 2011, 118 (21) : 1608 - 1609
  • [42] Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
    陈怡琳
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (03) : 181 - 181
  • [43] Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter in China
    Yu, Wenjuan
    Du, Xin
    Wang, Weiguang
    Lou, Jin
    Liu, Peng
    Meng, Li
    Jin, Jie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : E867 - E873
  • [44] Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
    Castagnetti, Fausto
    Pane, Fabrizio
    Rosti, Gianantonio
    Saglio, Giuseppe
    Breccia, Massimo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
    Molica, Matteo
    Scalzulli, Emilia
    Colafigli, Gioia
    Foa, Robin
    Breccia, Massimo
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [46] Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (10) : 2291 - 2291
  • [47] EVALUATION OF THE EFFECT AND SAFETY OF PONATINIB AS THIRD-LINE TREATMENT FOR PATIENTS WITH CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE
    Patir, P.
    Uysal, A.
    Duran, M.
    Soyer, N.
    Vural, F.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S28 - S28
  • [48] 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Lustgarten, Stephanie
    Santillana, Sergio
    Rivera, Victor M.
    Clackson, Tim
    Mueller, Martin C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S307 - S308
  • [49] CLINICAL ASPECTS OF NILOTINIB USE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE
    Gusarova, G. A.
    Turkina, A. G.
    Kolosheinova, T. I.
    Vakhrusheva, M. V.
    Chelysheva, E. Yu.
    Zakharova, E. S.
    Kuznetsov, S. V.
    Nemchenko, I. S.
    Sokolova, M. A.
    Goryacheva, S. R.
    Lazareva, O. V.
    Bykova, A. V.
    Tkhai, N. V.
    Khoroshko, N. D.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2012, 57 (04): : 3 - 11
  • [50] Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase
    Sasaki, Koji
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    O'Brien, Susan
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Takahashi, Koichi
    Jain, Preetesh
    Skinner, Jeffrey
    Rios, Mary Beth
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
12345